Watson Announces Approval of Nulecit, the First Generic Alternative to Ferrlecit for the Treatment of Iron Deficiency Anemia

Watson Pharmaceuticals, Inc. WPI today announced that it is initiating launch activities of Nulecit, following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application (ANDA). Nulecit is the first bioequivalent and therapeutically equivalent alternative to Sanofi-Aventis' Ferrlecit. In July 2009 Watson signed a license agreement with GeneraMedix for the exclusive U.S. marketing rights to the product, which will be marketed by Watson's Global Brands business.